<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443882</url>
  </required_header>
  <id_info>
    <org_study_id>01 2018 ver1</org_study_id>
    <nct_id>NCT03443882</nct_id>
  </id_info>
  <brief_title>Bioavailability of Astaxanthin Formulations</brief_title>
  <official_title>Bioavailability of Astaxanthin Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algatechnologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algatechnologies Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioavailability of dietary supplement formulations in healthy volunteers after a single oral
      dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of the bioavailability of 3 formulations with astaxanthin in healthy volunteers
      after single dose
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 25, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 2, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma level</measure>
    <time_frame>0-48 hr</time_frame>
    <description>astaxanthin in plasma</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Astaxanthin formulation #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astaxanthin formulation #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astaxanthin formulation #3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astaxanthin formulations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fast condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Astaxanthin</intervention_name>
    <description>an oral dose form</description>
    <arm_group_label>Astaxanthin formulation #1</arm_group_label>
    <arm_group_label>Astaxanthin formulation #2</arm_group_label>
    <arm_group_label>Astaxanthin formulation #3</arm_group_label>
    <arm_group_label>Astaxanthin formulations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have signed an informed consent form and who meet all of the following
             entrance criteria may be enrolled in this clinical trial: Generally, healthy men and
             women who are 21 to 50 years of age, inclusive, at the baseline visit.

        Exclusion Criteria:

          -  1. Are unwilling to follow the procedures of the trial, such as making visits or
             having their blood drawn.

             2. Have unintentionally lost or gained 10 or more kg of body weight in the last 3
             months; 3. Have an acute illness (such as a severe cold or flu) or have been
             hospitalized within the past month for certain conditions; 4. Have severe co-morbid
             disease including cardiac, pulmonary, renal, hepatic, carotid, peripheral vascular
             disease, stroke, neurological, clotting disorders or active cancer; 5. Taking chronic
             drugs which interfere with lipids metabolism (statins or similar) 6. Consume alcohol
             at an elevated level (Defined as consumption of more than 10 standard alcoholic drinks
             per week. A standard alcoholic drink is defined as one bottle/can of beer or one glass
             of wine equals one portion of hard liquor).

             7. Consume carotenoids as food supplements. 8. Have a Body Mass Index (BMI) of less
             than 17 or greater than 35 m/kg2; 9. Have participated in a clinical trial in the past
             4 weeks; 10. Have any disease or condition that in the investigator's opinion
             compromises the integrity of the clinical trial or the safety of the subject; 11.
             Smokers 12. Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Bitzur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bert W. Strassburger Lipid Center, Sheba Medical Center,</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>May 19, 2019</last_update_submitted>
  <last_update_submitted_qc>May 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

